Hyderabad, India, May 6, 2015: Mapmygenome India announced that their Spoligo TB™ in vitro diagnostic test kit for speedy detection and typing of large number of TB samples has been awarded the CE Certificate. With this move, the kit is all set to enter the Global market as a diagnostic device. Until now, the kit has been used extensively in Africa, South America, and Europe as in vitro research use only device.
Anu Acharya, CEO of Mapmygenome, said, “Spoligo TB™ has been one of our most consistent performers and now we can take this further to diagnostic labs across the globe. CE certification is a key milestone in achieving our vision of better health for India (and globally) using technology.”
About CE Certified Spoligo TB™ Kit
CE certified Spoligo TB™ is an effective PCR-based method to simultaneously detect and categorize Mycobacterium tuberculosis complex. Spoligo TB™ utilizes the technology of DNA polymorphism which is present at a particular chromosomal locus, the Direct Repeat (DR) region, which is unique to Mycobacterium tuberculosis complex bacteria. Researchers have proven that this test is superior to traditional tests such as Southern blotting, IS6110 fingerprinting, tuberculin skin test, culture, and sputum smear microscopy in terms of one or more of the following – accuracy, sensitivity, specificity, simplicity, throughput, costs, scale, and diagnosis time.
This kit finds applications in clinical samples, urban and rural labs for TB surveillance, and in large scale epidemiological control – in prison outbreaks, hospitals, and other closed communities. Information obtained from Spoligo TB™ is useful in the therapeutic management of tuberculosis. This test can also be used to screen TB infections in HIV patients
About Mapmygenome India
Mapmygenome India offers a variety of services in the domains of personal genomics, molecular diagnostics, DNA forensics, and brain wellness. Their products and services can be purchased from their stores online (www.mapmygenome.in), through their e-commerce partners such as SnapDeal.com or amazon.in, or from their wide network of diagnostics and hospital partners.
As pioneers of personal genomics in India, they created a new market in the country for predictive tests with their flagship brand Genomepatri™ in April 2013. In February 2014, the Government of Karnataka awarded them the Bio Excellence award “Emerging Company of the Year”. In March 2015, they raised a US $ 1.1 million Pre Series A rounding of funding from multiple sources.
Personal genomics products provide insights into the genetic basis of individuals’ health, including traits, lifestyle, drug responses, inherited conditions, and diseases. By combining genetic report and health history with genetic counseling, Mapmygenome provides actionable steps for individuals and their physicians towards a healthier life.
Molecular diagnostics are tests recommended by doctors for cancer, cardiovascular, neuromuscular, and other key conditions.
Mapmygenome also offers molecular tests for TB and other infectious diseases that increase accuracy at very low costs. CE certified Spoligo TB™ is one such test.
DNA Forensics include maternity, paternity, sibling, and other identification tests.
Brain wellness includes a series of assessments for improving emotional and cognitive efficacy, for assessing leadership skills, and more.
For more information, visit www.mapmygenome.in.